Competition in generic drugs continues to fall dramatically
2021-05-23 10:03:51
With the advent of generic competition, the cost of prescription drugs paid by millions of patients each day will be greatly reduced. In the next 14 months, 7 of the top 20 branded drugs in the world will compete with generic drugs. Including the top 2 lipid-lowering drugs atorvastatin calcium tablets (lipitor) and anticoagulant clopidogrel sulfate tablets (Plavix). The global number of drugs facing patent expiration is so great that it is unprecedented. From this year to 2016, patent expired "blockbuster" global sales of up to 255 billion US dollars. The best-selling drugs that face the expiration of patents cover areas such as hypertension, asthma, diabetes, depression, high blood cholesterol, AIDS, and bipolar disorder.
In the United States, more than 15% of the population are taking drugs whose 2011-2012 patent expires. Since the price of generic drugs is 20%-80% lower than that of branded drugs, both business owners and taxpayers who pay for prescription drugs through corporate and government prescription drug plans can save money due to the launch of generic drugs. The proportion of prescriptions for generic drugs in the United States rose from 57% in 2004 to 78% in 2010. According to the report of the American Generic Manufacturers Association, from 2000 to 2009, generics saved US$824 billion for the U.S. health care system, which now saves one billion U.S. dollars every three days.
Doctors hope that low-priced generic drugs can reduce some patients' injuries caused by the economic pressure of brand drugs. Because the cost of brand drugs is too high, patients may reduce their own dose or fail to comply with doctor's orders. Even individuals with personal insurance or medical insurance do not reach the required doses for prescription drugs, which are more common in expensive oncology drugs.
The bioequivalence of the generic drugs and the original brand drugs is the same, and the effects are comparable. In the first 6 months after the drug was lost, there was usually only one type of generic drug on the market, so the price of generic drugs was only slightly lower than that of brand drugs. However, when several generic generic drugs are approved for marketing, the price of drugs will be significantly reduced.
Original research drug company is accelerating the loss caused by the adjustment of the patent cliff. In particular, in the final year prior to the launch of generic drugs, the original research company had increased its drug prices by more than 20% in order to maximize its revenue. In addition, some invented pharmaceutical companies and generic pharmaceutical companies signed contracts, and generic companies paid a portion of their sales revenue to the original research company in order to obtain the original research company's license to produce “authorized generic drugs.†The original research company also cuts its R&D budget, shares the cost of drug development with other companies' shareholders, and transfers to low-cost countries for clinical research and production.
In the 1990s, pharmaceutical giants developed a large number of "bombshell" drugs that patients could take for long periods of time. To this day, millions of patients take these medicines every day. Compared with prescription drugs used for short-term treatment, these “bombshell†drugs have more profit margins. In recent years, many pharmaceutical companies have committed to developing new "bombshell" drugs. Despite billions of dollars in R&D budgets and the participation of many scientists, the success rate is still very low. Part of the reason is that the discovered products can only solve the anemia problem of pharmaceutical giants in a short period of time. A variety of products such as Lipitor is difficult to duplicate. In terms of the same field, not only is the product's own advantage difficult to overcome, but it is also difficult to find new breakthrough points.
In the United States, more than 15% of the population are taking drugs whose 2011-2012 patent expires. Since the price of generic drugs is 20%-80% lower than that of branded drugs, both business owners and taxpayers who pay for prescription drugs through corporate and government prescription drug plans can save money due to the launch of generic drugs. The proportion of prescriptions for generic drugs in the United States rose from 57% in 2004 to 78% in 2010. According to the report of the American Generic Manufacturers Association, from 2000 to 2009, generics saved US$824 billion for the U.S. health care system, which now saves one billion U.S. dollars every three days.
Doctors hope that low-priced generic drugs can reduce some patients' injuries caused by the economic pressure of brand drugs. Because the cost of brand drugs is too high, patients may reduce their own dose or fail to comply with doctor's orders. Even individuals with personal insurance or medical insurance do not reach the required doses for prescription drugs, which are more common in expensive oncology drugs.
The bioequivalence of the generic drugs and the original brand drugs is the same, and the effects are comparable. In the first 6 months after the drug was lost, there was usually only one type of generic drug on the market, so the price of generic drugs was only slightly lower than that of brand drugs. However, when several generic generic drugs are approved for marketing, the price of drugs will be significantly reduced.
Original research drug company is accelerating the loss caused by the adjustment of the patent cliff. In particular, in the final year prior to the launch of generic drugs, the original research company had increased its drug prices by more than 20% in order to maximize its revenue. In addition, some invented pharmaceutical companies and generic pharmaceutical companies signed contracts, and generic companies paid a portion of their sales revenue to the original research company in order to obtain the original research company's license to produce “authorized generic drugs.†The original research company also cuts its R&D budget, shares the cost of drug development with other companies' shareholders, and transfers to low-cost countries for clinical research and production.
In the 1990s, pharmaceutical giants developed a large number of "bombshell" drugs that patients could take for long periods of time. To this day, millions of patients take these medicines every day. Compared with prescription drugs used for short-term treatment, these “bombshell†drugs have more profit margins. In recent years, many pharmaceutical companies have committed to developing new "bombshell" drugs. Despite billions of dollars in R&D budgets and the participation of many scientists, the success rate is still very low. Part of the reason is that the discovered products can only solve the anemia problem of pharmaceutical giants in a short period of time. A variety of products such as Lipitor is difficult to duplicate. In terms of the same field, not only is the product's own advantage difficult to overcome, but it is also difficult to find new breakthrough points.
Antioxidants Vitamins,Antioxidant Vitamins Tablets,Rubber Antioxygen,Antioxidants Free Radicals
SHANDONG BAISHENG BIOTECHNOLOGY COM , https://www.baishengbioproducts.com